Sekisui Highlights Rapid Testing and Clinical Chemistry Solutions at MEDICA 2026
Posted on 16 Nov 2026
Sekisui Diagnostics (Burlington, MA, USA) is showcasing a range of diagnostic products and raw materials at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. The company's exhibit highlights four key areas: the OSOM family of rapid tests, clinical chemistry reagents, diagnostic enzymes, and blood collection tube raw materials. These offerings support healthcare providers, clinical laboratories, and diagnostic manufacturers across applications ranging from point-of-care infectious disease testing to automated laboratory analysis and specimen preparation.
Among the featured products is the OSOM Rapid Test Family, which provides point-of-care testing solutions for infectious diseases and women's health. The portfolio includes tests for influenza, Group A Streptococcus, and Trichomonas vaginalis, as well as other respiratory and infectious conditions. Designed for straightforward use with minimal hands-on steps, the tests enable healthcare providers to obtain results during a patient visit and make timely treatment decisions. Most OSOM test kits incorporate QC Inside technology, which provides additional components for performing external quality control procedures.
In clinical chemistry, Sekisui is presenting its broad range of reagents for use on automated analyzers. The portfolio includes more than 65 reagents covering cardiovascular disease, diabetes, renal and liver function, therapeutic drug monitoring, and specialty assays. Its SEKURE open-channel reagents feature liquid-stable, ready-to-use formulations compatible with a variety of clinical chemistry platforms. The company also provides calibrators, controls, and linearity materials to support consistent analytical performance and routine laboratory quality assurance.
Another focus is Sekisui's portfolio of enzymes and specialty biochemicals used in clinical chemistry assays, biosensors, and diagnostic manufacturing. Products include cholesterol oxidase and glucose dehydrogenase for applications involving lipid metabolism and glucose measurement, along with enzymes supporting renal, pancreatic, cardiovascular, and liver function testing. The company's enzyme offerings also support point-of-care devices and blood glucose monitoring systems, with manufacturing capabilities extending from research and development quantities to commercial-scale production.
Sekisui is also highlighting raw materials for plastic vacuum blood collection tubes, including serum separation gels and clotting accelerants. These materials are designed to support efficient specimen processing and reliable separation of serum from blood cells while minimizing interference with subsequent laboratory testing. Its serum separation gel provides resistance to irradiation and helps maintain stable separation of blood clots and serum. Together, the four product areas demonstrate Sekisui's involvement in both finished diagnostic tests and essential components used throughout the laboratory testing process.